Vaximm

About:

Vaximm is a biotech firm that develops oral T-cell immunotherapies for patients suffering from cancer.

Top Investors: Merck, BioMedPartners, BB Biotech Ventures, Sunstone Life Science Ventures

Description:

Vaximm is focused on developing active immunotherapies (vaccines) for patients suffering from cancer. Their initial product candidate VXM01 is targeting the tumor vasculature, which is essential for tumors to grow beyond microscopic size. Vaximm has shown impressive anti-tumor activity in various animal studies and will enter first human clinical trials in 2011.

Total Funding Amount:

7.8M CHF

Estimated Revenue Range:

Less than $1M

Headquarters Location:

Basel, Basel-Stadt, Switzerland

Founded Date:

2008-01-01

Contact Email:

info(AT)vaximm.com

Founders:

Andreas Niethammer, Heinz Lubenau, Klaus Breiner

Number of Employees:

1-10

Last Funding Date:

2012-10-02

IPO Status:

Private

Industries: